{
    "meta": {
        "portal_name": "pharmacodynamics",
        "language": "en",
        "updated": "20150427"
    },
    "schema": {
        "html:portal": "http://en.recuweb.com/pharmacodynamics/",
        "graph:videos": "http://en.recuweb.com/graph/v1.0/pharmacodynamics/pharmacodynamics/videos.json",
        "graph:news": "http://en.recuweb.com/graph/v1.0/pharmacodynamics/pharmacodynamics/news.json",
        "graph:blogs": "http://en.recuweb.com/graph/v1.0/pharmacodynamics/pharmacodynamics/blogs.json"
    },
    "items": {
        "nephrologynews.com/2015/04/genzyme-begins-phase-2-clinical-trial-to-evaluate-oral-therapy": {
            "title": "Genzyme begins phase 2 clinical trial to evaluate oral therapy for Fabry disease...",
            "snippet": "Genzyme announced that patients have begun treatment in a Phase 2a clinical trial focused on evaluating the pharmacodynamics of GZ/SAR402671, a new oral substrate reduction therapy being investigated for the treatment of Fabry disease. The safety...",
            "date": "2015-04-23",
            "categories": "therapy,pharmacodynamics",
            "tags": "oral,oral-substrate,oral-substrate-reduction,substrate,substrate-reduction,substrate-reduction-therapy,reduction,reduction-therapy,reduction-therapy-being,therapy,therapy-being,therapy-being-investigated,investigated,treatment,clinical,clinical-trial,clinical-trial-focused,trial,trial-focused,focused,focused-on-evaluating,evaluating,announced,announced-that-patients,patients,patients-have-begun,begun,begun-treatment,evaluate,begins,phase,genzyme,fabry,disease,pharmacodynamics,sar,safety",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/nephrologynews.com/2015/04/genzyme-begins-phase-2-clinical-trial-to-evaluate-oral-therapy",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics&format=RSS&cc=us",
            "source_url": "http://nephrologynews.com/articles/110852-genzyme-begins-phase-2-clinical-trial-to-evaluate-oral-therapy-for-fabry-disease"
        },
        "live-pr.com/2015/04/quotient-clinical-completes-innovative-first-in-human-program": {
            "title": "Quotient Clinical completes innovative first-in-human program...",
            "snippet": "The integrated pharmaceutical development and first-in-human clinical program was designed to develop an optimal oral formulation, in parallel with the assessment of single and multiple dose safety, pharmacokinetics and pharmacodynamics of a...",
            "date": "2015-04-23",
            "categories": "pharmacokinetics,pharmacodynamics",
            "tags": "parallel,single,oral,clinical,designed,development,completes,dose,safety,pharmacokinetics,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/live-pr.com/2015/04/quotient-clinical-completes-innovative-first-in-human-program",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics&format=RSS&cc=us",
            "source_url": "http://live-pr.com/en/quotient-clinical-completes-innovative-first-in-human-r1050575730.htm"
        },
        "finanznachrichten.de/2015/04/sensorion-successfully-completes-the-first-part-of-clinical-trial-on-sens": {
            "title": "Sensorion Successfully Completes the First Part of the Clinical Trial on SENS-111, Which Aims to...",
            "snippet": "a pharmacodynamics test used in clinical practice by ENT specialists on patients suffering from dizziness. This study, for which the recruitment of healthy volunteers began in January 2015, comprises two parts: Part 1: a study of single oral doses...",
            "date": "2015-04-23",
            "categories": "recruitment,pharmacodynamics",
            "tags": "study,single,oral,part,patients,clinical,clinical_trial,trial,success,completes,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/finanznachrichten.de/2015/04/sensorion-successfully-completes-the-first-part-of-clinical-trial-on-sens",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics&format=RSS&cc=us",
            "source_url": "http://finanznachrichten.de/nachrichten-2015-04/33498318-sensorion-successfully-completes-the-first-part-of-the-clinical-trial-on-sens-111-which-aims-to-treat-severe-bouts-of-vertigo-004.htm"
        },
        "jobs.theconversation.com/2015/04/research-fellow-pharmacy-the-conversation-au": {
            "title": "Research Fellow (Pharmacy) - The Conversation AU...",
            "snippet": "Research Fellow (Pharmacy)The Conversation AUProfessor Li's group is employing a multidisciplinary approach (e.g. antimicrobial pharmacokinetics/pharmacodynamics, microbiology, biochemistry, genomics, transcriptomics, metabolomics and molecular...",
            "date": "2015-04-22",
            "categories": "pharmacokinetics,pharmacodynamics,biochemistry",
            "tags": "pharmacokinetics,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/biochemistry/jobs.theconversation.com/2015/04/research-fellow-pharmacy-the-conversation-au",
            "resource_url": "http://news.google.com/?hl=en&q=pharmacodynamics&output=atom&nord=1",
            "source_url": "http://jobs.theconversation.com/jobs/10325-research-fellow-pharmacy?utm_source=theconversation.com&utm_medium=website&utm_campaign=sidebar_job"
        },
        "thestreet.com/2015/04/arno-therapeutics-to-present-promising-data-from-phase-i-trial-of": {
            "title": "Arno Therapeutics To Present Promising Data From Phase I Trial Of Onapristone At AACR Annual...",
            "snippet": "with progesterone receptor (PR)-expressing cancers: PK results from part 1 of a randomized, parallel-dose phase 1 study Poster Session:. Pharmacokinetics and Pharmacodynamics Date, Location: Tuesday, April 21; 1:00-5:00 p.m. ET...",
            "date": "2015-04-21",
            "categories": "pharmacodynamics,cancer,pharmacokinetics",
            "tags": "pharmacodynamics,receptor,phase,trial,aacr,therapeutics,part,parallel,dose,study,pharmacokinetics",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/thestreet.com/2015/04/arno-therapeutics-to-present-promising-data-from-phase-i-trial-of",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics&format=RSS&cc=us",
            "source_url": "http://thestreet.com/story/13119643/1/arno-therapeutics-to-present-promising-data-from-phase-i-trial-of-onapristone-at-aacr-annual-meeting-2015.html"
        },
        "streetinsider.com/2015/04/genzyme-sny-begins-gz-sar402671-phase-2a-treatment": {
            "title": "Genzyme (SNY) Begins GZ/SAR402671 Phase 2a Treatment...",
            "snippet": "Genzyme, a Sanofi (NYSE: SNY) company, announced that patients have begun treatment in a Phase 2a clinical trial focused on evaluating the pharmacodynamics of GZ/SAR402671, a new oral substrate reduction therapy being investigated for the treatment...",
            "date": "2015-04-21",
            "categories": "therapy,pharmacodynamics",
            "tags": "oral,oral-substrate,oral-substrate-reduction,substrate,substrate-reduction,substrate-reduction-therapy,reduction,reduction-therapy,reduction-therapy-being,therapy,therapy-being,therapy-being-investigated,investigated,treatment,clinical,clinical-trial,clinical-trial-focused,trial,trial-focused,focused,focused-on-evaluating,evaluating,announced,announced-that-patients,patients,patients-have-begun,begun,begun-treatment,genzyme,begins,sar,phase,sanofi,company,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/streetinsider.com/2015/04/genzyme-sny-begins-gz-sar402671-phase-2a-treatment",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics&format=RSS&cc=us",
            "source_url": "http://streetinsider.com/Corporate+News/Genzyme+(SNY)+Begins+GZSAR402671+Phase+2a+Treatment/10475169.html"
        },
        "benzinga.com/2015/04/genzyme-initiates-phase-2a-clinical-trial-to-evaluate-oral-therapy": {
            "title": "Genzyme Initiates Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry... - Benzinga...",
            "snippet": "Genzyme Initiates Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry...BenzingaGenzyme, a Sanofi company, announced today that patients have begun treatment in a Phase 2a clinical trial focused on evaluating the pharmacodynamics of...",
            "date": "2015-04-21",
            "categories": "therapy,pharmacodynamics",
            "tags": "clinical,clinical_trial,clinical-trial-focused,trial,trial-focused,focused,focused-on-evaluating,evaluating,announced,announced-today,today,today-that-patients,patients,patients-have-begun,begun,begun-treatment,treatment,evaluate,evaluate_oral,evaluate_oral_therapy,oral,oral_therapy,therapy,genzyme,genzyme_initiates,genzyme_initiates_phase,initiates,initiates_phase,phase,fabry,sanofi,company,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/benzinga.com/2015/04/genzyme-initiates-phase-2a-clinical-trial-to-evaluate-oral-therapy",
            "resource_url": "http://news.google.com/?hl=en&q=pharmacodynamics&output=atom&nord=1",
            "source_url": "http://benzinga.com/news/15/04/5426554/genzyme-initiates-phase-2a-clinical-trial-to-evaluate-oral-therapy-for-fabry-dise"
        },
        "businesswire.com/2015/04/genzyme-initiates-phase-2a-clinical-trial-to-evaluate-oral-therapy": {
            "title": "Genzyme Initiates Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry Disease...",
            "snippet": "CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company, announced today that patients have begun treatment in a Phase 2a clinical trial focused on evaluating the pharmacodynamics of GZ/SAR402671, a new oral substrate reduction therapy being...",
            "date": "2015-04-21",
            "categories": "therapy,business,pharmacodynamics",
            "tags": "oral,oral-substrate,oral-substrate-reduction,substrate,substrate-reduction,substrate-reduction-therapy,reduction,reduction-therapy,reduction-therapy-being,therapy,therapy-being,clinical,clinical_trial,clinical-trial-focused,trial,trial-focused,focused,focused-on-evaluating,evaluating,announced,announced-today,today,today-that-patients,patients,patients-have-begun,begun,begun-treatment,treatment,fabry,disease,evaluate,evaluate_oral,evaluate_oral_therapy,oral_therapy,genzyme,genzyme_initiates,genzyme_initiates_phase,initiates,initiates_phase,phase,sanofi,company,pharmacodynamics,sar",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/businesswire.com/2015/04/genzyme-initiates-phase-2a-clinical-trial-to-evaluate-oral-therapy",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics&format=RSS&cc=us",
            "source_url": "http://businesswire.com/news/home/20150421005272/en/Genzyme-Initiates-Phase-2a-Clinical-Trial-Evaluate"
        },
        "fnno.com/2015/04/short-term-underperformance-detected-in-shares-of-nektar-therapeutics-the-pharmaceuticals": {
            "title": "Short-term Underperformance Detected in Shares of Nektar Therapeutics in the Pharmaceuticals...",
            "snippet": "Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Analyzing the price chart for...",
            "date": "2015-04-21",
            "categories": "metabolism,drugs,pharmacokinetics,pharmacodynamics,life",
            "tags": "metabolism,distribution,drugs,drug,designed,therapeutics,pharmacokinetics,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/life/fnno.com/2015/04/short-term-underperformance-detected-in-shares-of-nektar-therapeutics-the-pharmaceuticals",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics%2Bpharmacodynamics&format=RSS&cc=us",
            "source_url": "http://fnno.com/story/fast-lane/331-short-term-underperformance-detected-shares-nektar-therapeutics-pharmaceuticals-industry-nktr-mdco-bdsi-myl-"
        },
        "cancernetwork.com/2015/04/aacr-insulin-signaling-and-cancer-development-progression-network": {
            "title": "AACR: Insulin Signaling and Cancer Development, Progression - Cancer Network...",
            "snippet": "Cancer NetworkAACR: Insulin Signaling and Cancer Development, ProgressionCancer NetworkAs a matter of fact, some investigators believe that those toxicities are actually a pharmacodynamics readout that the target has been successfully engaged, at...",
            "date": "2015-04-20",
            "categories": "cancer,pharmacodynamics",
            "tags": "success,development,aacr,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/cancernetwork.com/2015/04/aacr-insulin-signaling-and-cancer-development-progression-network",
            "resource_url": "http://news.google.com/?hl=en&q=pharmacodynamics&output=atom&nord=1",
            "source_url": "http://cancernetwork.com/aacr-2015/aacr-insulin-signaling-and-cancer-development-progression"
        }
    }
}